Valsartan - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for valsartan and what is the scope of patent protection?

Valsartan is the generic ingredient in three branded drugs marketed by Novartis, Carmel Biosciences, Novitium Pharma, Alembic, Alkem Labs Ltd, Amneal Pharms, Aurobindo Pharma Ltd, Dr Reddys, Hetero Labs Ltd V, Ivax Pharms, Jubilant Generics, Lupin Ltd, Macleods Pharms Ltd, Mylan, Ohm Labs Inc, Prinston Inc, Sciegen Pharms Inc, Square Pharms, Torrent, Unichem, Watson Labs Inc, Zenara, and Zydus Lifesciences, and is included in twenty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are forty drug master file entries for valsartan. Thirty-six suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for valsartan

US Patents:	0
Tradenames:	3
Applicants:	23
NDAs:	24
Drug Master File Entries:	40
Finished Product Suppliers / Packagers:	36
Raw Ingredient (Bulk) Api Vendors:	152
Clinical Trials:	385
Patent Applications:	8,236
Drug Prices:	Drug price trends for valsartan
Drug Sales Revenues:	Drug sales revenues for valsartan
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for valsartan
What excipients (inactive ingredients) are in valsartan?	valsartan excipients list
DailyMed Link:	valsartan at DailyMed

See drug prices for valsartan

See drug sales revenues for valsartan

Recent Clinical Trials for valsartan

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
International Bio service	Phase 1
Dr. Reddy's Laboratories (Thailand) Limited	Phase 1
Rede de Investigação em Saúde	Phase 4

See all valsartan clinical trials

Generic filers with tentative approvals for VALSARTAN

Applicant	Application No.	Strength	Dosage Form
⤷ Sign Up	⤷ Sign Up	320MG; 12.5MG	TABLET; ORAL
⤷ Sign Up	⤷ Sign Up	160MG; 25MG	TABLET; ORAL
⤷ Sign Up	⤷ Sign Up	160MG; 12.5MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for valsartan

Drug Class	Angiotensin 2 Receptor Blocker
Mechanism of Action	Angiotensin 2 Receptor Antagonists

Medical Subject Heading (MeSH) Categories for valsartan

Angiotensin II Type 1 Receptor Blockers
Antihypertensive Agents

Anatomical Therapeutic Chemical (ATC) Classes for valsartan

C09CA	Angiotensin II receptor blockers (ARBs), plain
C09C	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

Paragraph IV (Patent) Challenges for VALSARTAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DIOVAN	Tablets	valsartan	40 mg, 80 mg, 160 mg and 320 mg	021283	1	2004-12-28

US Patents and Regulatory Information for valsartan

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	VALSARTAN	valsartan	TABLET;ORAL	091367-001	Jan 5, 2015	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Unichem	VALSARTAN	valsartan	TABLET;ORAL	209261-003	May 4, 2018		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Lupin Ltd	VALSARTAN	valsartan	TABLET;ORAL	201677-002	Jan 5, 2015	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Lupin Ltd	VALSARTAN	valsartan	TABLET;ORAL	201677-001	Jan 5, 2015	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ohm Labs Inc	VALSARTAN	valsartan	TABLET;ORAL	077492-001	Jun 26, 2014	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-003	Jul 18, 2001	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for valsartan

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-003	Jul 18, 2001	⤷ Sign Up	⤷ Sign Up
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-003	Jul 18, 2001	⤷ Sign Up	⤷ Sign Up
Novartis	DIOVAN	valsartan	CAPSULE;ORAL	020665-001	Dec 23, 1996	⤷ Sign Up	⤷ Sign Up
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-004	Aug 14, 2002	⤷ Sign Up	⤷ Sign Up
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-004	Aug 14, 2002	⤷ Sign Up	⤷ Sign Up
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-001	Jul 18, 2001	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.